Use of thiazolobenzoheterocycles for treating multiple sclerosis

1. A method of treating multiple sclerosis which comprises administering to a patient having multiple sclerosis a therapeutically effective amount of a compound of Formula I,

in which

R 1 is a sulphur or selenium atom,

R 2 is a hydrogen atom or an alkyl radical,

—R 3 —R 4 —R 5 —R 6 — is a chain of formula —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CO—, —CH 2 —CH 2 —CH 2 —CH(R 8 )—, —CH 2 —CH 2 —CH 2 —Se—, —CH 2 —CH 2 —Se—CH 2 —, —CH 2 —CH 2 —CH 2 —S—, —CH 2 —CH 2 —CH 2 —SO—, —CH 2 —CH 2 —CH 2 —SO 2 —, —CH 2 —CH 2 —CH 2 —O—, —CH 2 —CH 2 —CH 2 —N(R 9 )—, —CH 2 —CH 2 —CO—CH 2 —, —CH 2 —CH 2 —CH(R 8 )—CH 2 —, —CH 2 —CH 2 —S—CH 2 —, —CH 2 —CH 2 —SO—CH 2 —, —CH 2 —CH 2 —SO 2 —CH 2 —, —CH 2 —C(alk)(alk′)—S—CH 2 —, —CH 2 —C(alk)(alk′)—SO—CH 2 —, —CH 2 —C(alk)(alk′)—SO 2 —CH 2 —, —CH 2 —CH(R 10 )—S—CH 2 —, —CH 2 —CH(R 10 )—SO—CH 2 —, —CH 2 —CH(R 10 )—SO 2 —CH 2 —, —CH 2 —CH 2 —O—CH 2 —, —CH 2 —CH 2 —N(R 9 )—CH 2 — or —CH 2 —CO—N(R 9 )—CH 2 —,

R 7 is a polyfluoroalkyl or polyfluoroalkoxy radical,

R 8 is a hydroxyl radical,

R 9 is a hydrogen atom or an alkyl or benzyl radical,

R 10 is an alkyl, —CH 2 OH, —COOalk, —COOH or —CONH 2 radical,

alk is an alkyl radical,

alk′ is an alkyl radical,

the alkyl radicals containing 1 to 6 straight- or branched-chain carbon atoms,

and, when said compound contains one or more asymmetric centers, its isomers, racemates and enantiomers, and the salts of said compound with an inorganic or organic acid.

2. The method of claim 1 wherein, in said compound of formula 1, R 7 is a trifluoromethoxy or trifluoromethyl radical.

3. The method of claim 1 wherein, in said compound of formula 1, R 1 is a sulphur atom, R 2 is a hydrogen atom, —R 3 —R 4 —R 5 —R 6 — is a chain of formula —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CO—, —CH 2 —CH 2 —CH 2 —CH(R 8 )—, —CH 2 —CH 2 —CH 2 —Se—, —CH 2 —CH 2 —Se—CH 2 —, —CH 2 —CH 2 —CH 2 —S—, —CH 2 —CH 2 —CH 2 —SO—, —CH 2 —CH 2 —CH 2 —SO 2 —, —CH 2 —CH 2 —CH 2 —O—, —CH 2 —CH 2 —CH 2 —N(R 9 )—, —CH 2 —CH 2 —CO—CH 2 —, —CH 2 —CH 2 —CH(R 8 )—CH 2 —, —CH 2 —CH 2 —S—CH 2 —, —CH 2 —CH 2 —SO—CH 2 —, —CH 2 —CH 2 —SO 2 —CH 2 —, —CH 2 —C(alk)(alk′)—S—CH 2 —, —CH 2 —C(alk)(alk′)—SO—CH 2 —, —CH 2 —C(alk)(alk′)—SO 2 —CH 2 —, —CH 2 —CH(R 10 )—S—CH 2 —, —CH 2 —CH(R 10 )—SO—CH 2 —, —CH 2 —CH(R 10 )—SO 2 —CH 2 —, —CH 2 —CH 2 —O—CH 2 —, —CH 2 —CH 2 —N(R 9 )—CH 2 — or —CH 2 —CO—N(R 9 )—CH 2 —, R 7 is a trifluoromethyl or trifluoromethoxy radical, R 8 is a hydroxyl radical, R 9 is a hydrogen atom or an alkyl or benzyl radical, R 10 is an alkyl, —CH 2 OH, —COOalk, —COOH or —CONH 2 radical, alk is an alkyl radical and alk′ is an alkyl radical.

4. The method of claim 1 wherein, said compound of formula 1 is selected from the group consisting of:

2-imino-9-trifluoromethoxy-4,5,6,7-tetrahydro-2H-thiazolo[5,4,3-jk][1]benzazepin-7-ol,

2-imino-9-trifluoromethoxy-4,5,6,7-tetrahydro-2H-thiazolo[5,4,3-jk][1]benzazepine,

2-imino-9-trifluoromethyl-4,5,6,7-tetrahydro-2H-thiazolo[5,4,3-jk][1]benzazepine,

2-imino-9-trifluoromethoxy-5,6-dihydro-2H,4H-thiazolo[3,4,5-ef][1,5]benzothiazepine 7,7-dioxide,

2-imino-9-trifluoromethoxy-5,6-dihydro-2H,4H-thiazolo[3,4,5-ef][1,5]benzothiazepine 7-oxide,

2-imino-9-trifluoromethoxy-5,6-dihydro-2H,4H-thiazolo[3,4,5-ef][1,5]benzothiazepine,

6-benzyl-2-imino-9-trifluoromethoxy-6,7-dihydro-4H-thiazolo[3,4,5-kj][1,4]benzodiazepin-5-one,

6-benzyl-2-imino-9-trifluoromethoxy-4,5,6,7-tetrahydro-2H-thiazolo[3,4,5-kj][1,4]benzodiazepine,

2-imino-9-trifluoromethoxy-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine,

2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine,

2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine 6,6-dioxide,

2-imino-9-trifluoromethyl-5,6-dihydro-2H,4H-thiazolo[3,4,5-ef][1,5]benzothiazepine 7-oxide,

2-imino-9-trifluoromethyl-5,6-dihydro-2H,4H-thiazolo[3,4,5-ef][1,5]benzothiazepine 6,6-dioxide,

2-imino-9-trifluoromethyl-5,6-dihydro-2H,4H-thiazolo[3,4,5-ef][1,5]benzothiazepine,

2-imino-9-trifluoromethyl-4,5,6,7-tetrahydro-2H-thiazolo[5,4,3-jk][1]benzazepin-7-ol,

2-imino-9-trifluoromethoxy-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine 6,6-dioxide,

2-imino-9-trifluoromethoxy-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine 6-oxide,

6-benzyl-2-imino-9-trifluoromethyl-6,7-dihydro-4H-thiazolo[3,4,5-kj][1,4]benzodiazepin-5-one,

6-benzyl-2-imino-9-trifluoromethyl-4,5,6,7-tetrahydro-2H-thiazolo[3,4,5-kj][1,4]benzodiazepine,

2-imino-5-methyl-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine,

5-carbamoyl-2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine,

5,5-dimethyl-2-imino-9-trifluoromethyl-2H,4H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine,

5-hydroxymethyl-2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine,

and, when they contain one or more asymmetric centres, their isomers, racemates, enantiomers and their salts with an inorganic or organic acid.

5. The method of claim 1 wherein, said compound of formula 1 is selected from the group consisting of:

(R,S)-2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine-6-oxide,

(+)-2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine-6-oxide,

(−)-2-imino-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine-6-oxide,

(R,S)-2-imino-5-methyl-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine-6,6-dioxide,

(+)-2-imino-5-methyl-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine-6,6-dioxide,

(−)-2-imino-5-methyl-9-trifluoromethyl-4,5-dihydro-2H,7H-thiazolo[3,4,5-de][4,1]benzothiazepine-6,6-dioxide,

and their salts with an inorganic or organic acid.

6. A method of treating inflammatory or neuropathic pain comprising administering to a patient in need thereof an effective amount of a compound of formula I as defined in claim 1 .

7. The method of claim 6 wherein said pain is associated with multiple sclerosis.